Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

IRVINE, Calif.: IRVINE, Calif., Nov. 15, 2021 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the...

Click to view original post